Risk of Late Toxicity in Men Receiving Dose-Escalated Hypofractionated Intensity Modulated Prostate Radiation Therapy: Results From a Randomized Trial


      To report late toxicity outcomes from a randomized trial comparing conventional and hypofractionated prostate radiation therapy and to identify dosimetric and clinical parameters associated with late toxicity after hypofractionated treatment.

      Methods and Materials

      Men with localized prostate cancer were enrolled in a trial that randomized men to either conventionally fractionated intensity modulated radiation therapy (CIMRT, 75.6 Gy in 1.8-Gy fractions) or to dose-escalated hypofractionated IMRT (HIMRT, 72 Gy in 2.4-Gy fractions). Late (≥90 days after completion of radiation therapy) genitourinary (GU) and gastrointestinal (GI) toxicity were prospectively evaluated and scored according to modified Radiation Therapy Oncology Group criteria.


      101 men received CIMRT and 102 men received HIMRT. The median age was 68, and the median follow-up time was 6.0 years. Twenty-eight percent had low-risk, 71% had intermediate-risk, and 1% had high-risk disease. There was no difference in late GU toxicity in men treated with CIMRT and HIMRT. The actuarial 5-year grade ≥2 GU toxicity was 16.5% after CIMRT and 15.8% after HIMRT (P=.97). There was a nonsignificant numeric increase in late GI toxicity in men treated with HIMRT compared with men treated with CIMRT. The actuarial 5-year grade ≥2 GI toxicity was 5.1% after CIMRT and 10.0% after HIMRT (P=.11). In men receiving HIMRT, the proportion of rectum receiving 36.9 Gy, 46.2 Gy, 64.6 Gy, and 73.9 Gy was associated with the development of late GI toxicity (P<.05). The 5-year actuarial grade ≥2 GI toxicity was 27.3% in men with R64.6Gy ≥ 20% but only 6.0% in men with R64.6Gy < 20% (P=.016).


      Dose-escalated IMRT using a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can be delivered safely with limited grade 2 or 3 late toxicity. Minimizing the proportion of rectum that receives moderate and high dose decreases the risk of late rectal toxicity after this hypofractionation regimen.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kuban D.A.
        • Tucker S.L.
        • Dong L.
        • et al.
        Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 67-74
        • Peeters S.T.
        • Heemsbergen W.D.
        • Koper P.C.
        • et al.
        Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
        J Clin Oncol. 2006; 24: 1990-1996
        • Zietman A.L.
        • DeSilvio M.L.
        • Slater J.D.
        • et al.
        Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial.
        JAMA. 2005; 294: 1233-1239
        • Brenner D.J.
        • Hall E.J.
        Fractionation and protraction for radiotherapy of prostate carcinoma.
        Int J Radiat Oncol Biol Phys. 1999; 43: 1095-1101
        • Brenner D.J.
        • Martinez A.A.
        • Edmundson G.K.
        • et al.
        Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue.
        Int J Radiat Oncol Biol Phys. 2002; 52: 6-13
        • Fowler J.
        • Chappell R.
        • Ritter M.
        Is alpha/beta for prostate tumors really low?.
        Int J Radiat Oncol Biol Phys. 2001; 50: 1021-1031
        • King C.R.
        • Fowler J.F.
        A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low.
        Int J Radiat Oncol Biol Phys. 2001; 51: 213-214
        • Konski A.A.
        Less is more: Will hypofractionated radiotherapy negatively affect cancer centers or be a Godsend in the new health care environment?.
        Oncology (Williston Park). 2012; 26: 522-523
        • Sethukavalan P.
        • Cheung P.
        • Tang C.I.
        • et al.
        Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: The benefits of hypofractionated over conventionally fractionated radiotherapy.
        Can J Urol. 2012; 19: 6165-6169
        • Cox J.D.
        • Stetz J.
        • Pajak T.F.
        Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).
        Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346
        • Barry M.J.
        • Fowler Jr., F.J.
        • O'Leary M.P.
        • et al.
        The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.
        J Urol. 1992; 148 (discussion 1564): 1549-1557
        • Brenner D.J.
        Fractionation and late rectal toxicity.
        Int J Radiat Oncol Biol Phys. 2004; 60: 1013-1015
        • Tucker S.L.
        • Thames H.D.
        • Michalski J.M.
        • et al.
        Estimation of alpha/beta for late rectal toxicity based on RTOG 94-06.
        Int J Radiat Oncol Biol Phys. 2011; 81: 600-605
        • Budaus L.
        • Bolla M.
        • Bossi A.
        • et al.
        Functional outcomes and complications following radiation therapy for prostate cancer: A critical analysis of the literature.
        Eur Urol. 2012; 61: 112-127
      1. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer V2.2013. Available at Accessed June 26, 2013.

        • Zaorsky N.G.
        • Ohri N.
        • Showalter T.N.
        • et al.
        Systematic review of hypofractionated radiation therapy for prostate cancer.
        Cancer Treat Rev. 2013; 39: 728-736
        • Ritter M.
        • Forman J.
        • Kupelian P.
        • et al.
        Hypofractionation for prostate cancer.
        Cancer J. 2009; 15: 1-6
        • Miles E.F.
        • Lee W.R.
        Hypofractionation for prostate cancer: A critical review.
        Semin Radiat Oncol. 2008; 18: 41-47
        • Pollack A.
        • Walker G.
        • Horwitz E.M.
        • et al.
        Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer.
        J Clin Oncol. 2013; 31: 3860-3868
        • Kupelian P.A.
        • Thakkar V.V.
        • Khuntia D.
        • et al.
        Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes.
        Int J Radiat Oncol Biol Phys. 2005; 63: 1463-1468
        • Kupelian P.A.
        • Willoughby T.R.
        • Reddy C.A.
        • et al.
        Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
        Int J Radiat Oncol Biol Phys. 2007; 68: 1424-1430
        • Michalski J.M.
        • Gay H.
        • Jackson A.
        • et al.
        Radiation dose-volume effects in radiation-induced rectal injury.
        Int J Radiat Oncol Biol Phys. 2010; 76: S123-S129
        • Malik R.
        • Jani A.B.
        • Liauw S.L.
        External beam radiotherapy for prostate cancer: Urinary outcomes for men with high International Prostate Symptom Scores (IPSS).
        Int J Radiat Oncol Biol Phys. 2011; 80: 1080-1086
        • Aizer A.A.
        • Anderson N.S.
        • Oh S.C.
        • et al.
        The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy.
        Int J Radiat Oncol Biol Phys. 2011; 79: 379-384
        • Harsolia A.
        • Vargas C.
        • Yan D.
        • et al.
        Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: Dose-volume analysis of a phase II dose-escalation study.
        Int J Radiat Oncol Biol Phys. 2007; 69: 1100-1109
        • Zelefsky M.J.
        • Cowen D.
        • Fuks Z.
        • et al.
        Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.
        Cancer. 1999; 85: 2460-2468
        • Storey M.R.
        • Pollack A.
        • Zagars G.
        • et al.
        Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial.
        Int J Radiat Oncol Biol Phys. 2000; 48: 635-642
        • Boersma L.J.
        • van den Brink M.
        • Bruce A.M.
        • et al.
        Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms.
        Int J Radiat Oncol Biol Phys. 1998; 41: 83-92


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.